A multicenter retrospective study assessing the safety, efficacy, and prescription patterns of direct oral anticoagulants (DOACs) in young adults with acute Venous Thromboembolism
Latest Information Update: 02 Sep 2021
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 02 Sep 2021 New trial record